Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Galderma initiates phase II trial of NP-000888 for plaque and nail psoriasis

Feb. 17, 2017

FDA approves Siliq for plaque psoriasis

Feb. 16, 2017

MediWound reports favorable results from phase II study of NexoBrid

Feb. 10, 2017

Vyome Biosciences announces promising results for VB-1953

Feb. 8, 2017

Sirnaomics initiates first-in-human study of STP-705

Feb. 7, 2017

Merck KGaA discloses novel BTK inhibitors

Feb. 1, 2017

MediWound's phase II study of EscharEx meets primary endpoint

Feb. 1, 2017

Topline results from two pivotal phase III trials of SB-204 in patients with acne vulgaris

Jan. 30, 2017

Merck KGaA reports findings from phase Ib study of M-1095 in psoriasis

Jan. 26, 2017

FDA approves Rhofade, Allergan's topical treatment for persistent facial erythema

Jan. 20, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 25, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026